Sharescart Research Club logo
Products
Research
Tools
About
Join Channel

Laurus Labs

₹966.4 -19.8 | 2%

Last updated: 15:58

Consolidated Standalone

Last updated: 15:58

Laurus Labs Overview

Laurus Labs Ltd is an India-based producer of active pharmaceutical ingredients (APIs) for anti-etrovirals (ARVs), oncology, cardiovascular, anti-diabetics, anti-asthma and gastroenterology. The Company develops and manufactures oral stable formulations, gives contract research and manufacturing services (CRAMS) and contract development and manufacturing company (CDMO) to the global pharmaceutical companies. The Company also produces special substances for nutraceuticals, dietary supplements, and cosmeceuticals. Its business gadgets includes Ge...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Laurus Labs Key Financials

Market Cap ₹52169 Cr.

Stock P/E 147.2

P/B 10.3

Current Price ₹966.4

Book Value ₹ 93.7

Face Value 2

52W High ₹1140.9

Dividend Yield 0.12%

52W Low ₹ 512.1

Edit Ratio

Laurus Labs Share Price

₹ | |

Volume
Price

Laurus Labs Quarterly Price

Quarterly Monthly
Show Value Show %

Laurus Labs Peer Comparison

Laurus Labs Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 1224 1195 1440 1195 1224 1415 1720 1570 1653 1778
Other Income 2 2 19 3 5 9 59 10 27 6
Total Income 1226 1197 1458 1197 1228 1424 1779 1580 1680 1784
Total Expenditure 1037 1014 1198 1024 1045 1130 1300 1187 1250 1298
Operating Profit 190 184 260 174 183 295 479 393 430 486
Interest 42 51 51 49 53 58 56 52 40 39
Depreciation 93 98 102 106 108 106 110 117 120 121
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 54 35 107 18 23 131 312 224 270 327
Provision for Tax 15 9 32 6 5 40 78 63 76 73
Profit After Tax 39 25 75 12 18 91 234 161 194 253
Adjustments -2 -2 0 0 2 2 -0 2 1 -1
Profit After Adjustments 37 23 76 13 20 92 234 163 195 252
Adjusted Earnings Per Share 0.7 0.4 1.4 0.2 0.4 1.7 4.3 3 3.6 4.7

Laurus Labs Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1327 1778 1905 2056 2292 2832 4814 4936 6041 5041 5554 6721
Other Income 34 4 33 29 16 6 24 15 6 26 75 102
Total Income 1361 1782 1938 2085 2308 2838 4837 4951 6047 5067 5629 6823
Total Expenditure 1131 1415 1497 1643 1936 2267 3263 3513 4448 4263 4499 5035
Operating Profit 229 367 441 443 372 570 1574 1438 1598 804 1130 1788
Interest 101 111 100 80 88 90 68 102 165 183 216 187
Depreciation 62 86 106 125 164 187 205 251 324 385 430 468
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 67 169 235 237 120 294 1301 1084 1109 236 484 1133
Provision for Tax -2 35 44 70 26 38 317 251 312 68 130 290
Profit After Tax 68 134 191 168 94 255 984 832 797 168 354 842
Adjustments 0 -0 -1 0 0 0 -0 -5 -12 -11 4 2
Profit After Adjustments 68 134 190 168 94 255 984 828 785 158 358 844
Adjusted Earnings Per Share 2.2 4.2 3.6 3.2 1.8 4.8 18.3 15.4 14.6 2.9 6.6 15.6

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 10% 4% 14% 15%
Operating Profit CAGR 41% -8% 15% 17%
PAT CAGR 111% -25% 7% 18%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 54% 42% 22% NA%
ROE Average 8% 11% 21% 17%
ROCE Average 10% 13% 21% 17%

Laurus Labs Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 722 857 1330 1483 1558 1770 2598 3351 4038 4111 4473
Minority's Interest 0 0 0 0 0 0 3 8 11 5 130
Borrowings 304 460 125 142 259 165 429 596 761 798 646
Other Non-Current Liabilities 60 -32 8 33 37 49 264 332 418 361 548
Total Current Liabilities 802 884 1121 1307 1424 1692 2457 2681 2432 3112 3540
Total Liabilities 1888 2169 2584 2964 3278 3676 5751 6968 7660 8387 9336
Fixed Assets 801 1021 1230 1481 1629 1726 2171 2652 3409 3890 4123
Other Non-Current Assets 223 145 214 235 186 138 505 971 790 662 880
Total Current Assets 862 1003 1140 1248 1463 1812 3075 3345 3462 3835 4332
Total Assets 1888 2169 2584 2964 3278 3676 5751 6968 7660 8387 9336

Laurus Labs Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 15 40 13 2 3 3 2 48 75 46 139
Cash Flow from Operating Activities -65 182 332 342 298 347 733 911 994 666 602
Cash Flow from Investing Activities -397 -312 -289 -384 -253 -221 -941 -914 -996 -822 -682
Cash Flow from Financing Activities 486 103 -54 42 -45 -128 255 30 -27 250 39
Net Cash Inflow / Outflow 24 -27 -10 1 0 -1 47 27 -29 93 -41
Closing Cash & Cash Equivalent 40 13 2 3 3 2 48 75 46 139 100

Laurus Labs Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 2.2 4.24 3.56 3.16 1.76 4.78 18.33 15.4 14.56 2.93 6.64
CEPS(Rs) 4.18 6.99 5.62 5.53 4.85 8.28 22.16 20.17 20.81 10.26 14.55
DPS(Rs) 0 0.4 0.3 0.3 0.3 0.5 2 2 2 0.8 1.2
Book NAV/Share(Rs) 20.98 24.96 25.05 27.86 29.18 33.02 48.32 62.19 74.73 75.88 82.46
Core EBITDA Margin(%) 14.58 20 21.1 19.98 15.53 19.94 32.22 28.82 26.36 15.42 19
EBIT Margin(%) 12.53 15.47 17.35 15.32 9.07 13.53 28.45 24.03 21.09 8.32 12.61
Pre Tax Margin(%) 4.98 9.33 12.18 11.47 5.22 10.37 27.03 21.96 18.36 4.69 8.72
PAT Margin (%) 5.09 7.41 9.91 8.1 4.09 9.01 20.44 16.87 13.19 3.34 6.38
Cash Profit Margin (%) 9.69 12.18 15.39 14.16 11.26 15.63 24.7 21.96 18.55 10.97 14.13
ROA(%) 4.31 6.61 8.05 6.04 3 7.34 20.87 13.09 10.89 2.1 4
ROE(%) 14.47 18.65 18.12 11.97 6.19 15.39 45.15 28.05 21.63 4.15 8.3
ROCE(%) 13.74 16.35 16.52 13.68 8.22 14.14 39.82 25.97 22.97 6.64 10.16
Receivable days 65.47 73.56 95.66 100.4 101.97 96.76 79.52 98.37 88.66 117.42 120.6
Inventory Days 109.61 97 94.12 96.48 100.87 102.29 94.05 123.34 104.09 127.81 124.27
Payable days 101.84 87.3 94.21 99.44 119.3 145.69 155.37 175.76 106.1 135.42 153.14
PER(x) 0 0 28.91 31.83 45.38 13.51 19.75 38.31 20.12 133.9 92.37
Price/Book(x) 0 0 4.11 3.61 2.74 1.95 7.49 9.49 3.92 5.16 7.44
Dividend Yield(%) 0 0 0.29 0.3 0.38 0.77 0.55 0.34 0.68 0.2 0.2
EV/Net Sales(x) 0.64 0.61 3.3 3.07 2.31 1.59 4.33 6.76 2.93 4.66 6.42
EV/Core EBITDA(x) 3.68 2.95 14.25 14.26 14.21 7.9 13.23 23.2 11.08 29.21 31.54
Net Sales Growth(%) 14.39 34 7.15 7.96 11.47 23.55 69.99 2.54 22.39 -16.55 10.18
EBIT Growth(%) -6.62 67.08 19.61 -5.38 -34.42 84.28 257.33 -13.37 7.41 -67.09 67.03
PAT Growth(%) -29.93 96.91 42.64 -12.4 -44.06 172.25 285.4 -15.39 -4.3 -78.89 110.7
EPS Growth(%) -30.27 92.45 -15.95 -11.31 -44.27 171.04 283.84 -15.98 -5.42 -79.91 127.12
Debt/Equity(x) 1.14 1.2 0.64 0.66 0.67 0.6 0.56 0.52 0.49 0.61 0.61
Current Ratio(x) 1.07 1.13 1.02 0.95 1.03 1.07 1.25 1.25 1.42 1.23 1.22
Quick Ratio(x) 0.48 0.58 0.56 0.51 0.55 0.54 0.61 0.59 0.73 0.64 0.68
Interest Cover(x) 1.66 2.52 3.35 3.98 2.36 4.28 20.09 11.59 7.71 2.29 3.24
Total Debt/Mcap(x) 0 0 0.15 0.18 0.24 0.31 0.07 0.05 0.12 0.12 0.08

Laurus Labs Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 27.2 27.19 27.19 27.18 27.18 27.62 27.62 27.59 27.59 27.49
FII 24.03 25.39 25.97 25.67 26.08 25.56 25.52 25.7 26.16 26.52
DII 11.01 11.13 11.77 13.56 13.05 12.74 11.77 11.94 11.73 12.42
Public 37.76 36.29 35.07 33.59 33.69 34.08 35.09 34.78 34.51 33.56
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Laurus Labs News

Laurus Labs Pros & Cons

Pros

  • Company has reduced debt.

Cons

  • Promoter holding is low: 27.49%.
  • Company has a low return on equity of 11% over the last 3 years.
  • Debtor days have increased from 135.42 to 153.14days.
  • Stock is trading at 10.3 times its book value.
  • The company has delivered a poor profit growth of 6% over past five years.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!